 |
|
|
| |
Single doses of gatuzosiran (GSK4532990) produce sustained HSD17B13 suppression and liver biochemical improvement in patients with metabolic dysfunction-associated steatohepatitis
|
| |
| |
EASL 2026 May 26-30 Barcelona
Download the PDF here here
Eric Lawitz1, Itziar Irurzun-Arana2, Nitendra Agarwal3, Nomita Kim4, Raj Vuppalanchi5, Kathy-Ann Cadogan6*,
Hardik Chandasana6*, Marc Goldfinger7, Chronis Kemos8, Andrea Ribeiro9, Brandon Swift10, Mee J. Kim11
1Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 2Clinical Pharmacology & Quantitative Medicine, GSK, Madrid, Spain; 3ERG Clinical, San Antonio, TX, USA; 4IMA Clinical Research, Austin, TX, USA; 5Indiana University School of Medicine, Indianapolis, IN, USA; 6Clinical Pharmacology & Quantitative Medicine, GSK, Collegeville, PA, USA; 7Translational Science, GSK, London, UK; 8RII Statistics - F&I, Hepatology & Neuro, GSK, Stevenage, UK; 9RIIRU Hepatology Research Unit, GSK, Madrid, Spain;
10Clinical Pharmacology & Quantitative Medicine, GSK, Durham, NC, USA; 11RIIRU Hepatology Research Unit, GSK, Philadelphia, PA, USA. *At the time of the study.
|
| |
|
|
|
|
|
